Key clinical point: This real-world study validated the efficacy of upadacitinib and elucidated the variables influencing the attainment of minimal disease activity (MDA) in response to upadacitinib therapy in patients with psoriatic arthritis (PsA).
Major finding: At week 24, nearly half (47%) of the patients treated with upadacitinib achieved MDA, with males (odds ratio [OR] 2.54; P = .043), patients naive to biologic disease-modifying antirheumatic drugs (OR 4.13; P = .013), and patients with high baseline C-reactive protein levels (OR 2.49; P = .046) having higher odds of achieving MDA.
Study details: Findings are from the preliminary results of the ongoing UPREAL-PsA study including 126 patients with peripheral or axial PsA who received 15 mg upadacitinib once daily.
Disclosures: This study did not receive any specific funding. The authors declared no conflicts of interest.
Source: Luchetti Gentiloni MM et al. Upadacitinib effectiveness and factors associated with minimal disease activity achievement in patients with psoriatic arthritis: Preliminary data of a real-life multicenter study. Arthritis Res Ther. 2023;25:196. (Oct 11). doi: 10.1186/s13075-023-03182-9